Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$87.01M$87.01Mderived+0.8% vs Q4 2024 Net Income-$2.33M-$2.33MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,827,000N/M Operating Cash Flowderived$26,931,000+10.5% Free Cash Flowderived$19,747,000+17.6% Margins · derivedOperating margin-4.4%−9.1 pt vs Q4 2024
Net margin-2.7%−13.8 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end